The issuer is solely responsible for the content of this announcement.

Cash runway extended to end of 2014

Addex Therapeutics (SIX: ADXN) announced
today that it has raised gross proceeds of CHF3.2 million (US$3.5 million)
in a
private placement of 1,170,612 new issued registered shares to
international
institutional investors with extensive life science experience. The
private
placement was strongly supported by existing investors including BVF
Partners
L.P., which manages the Biotechnology Value Fund, and new investors,
including
Armistice Capital, which as a result of the placement will hold 5.36%
of the
issued share capital after the transaction, and EcoR1 Capital. Board
Members and
Executive Management also participated in the private placement.

"These funds have extended our cash runway through 2014 taking us
beyond our
next significant clinical event, the reporting of Phase 2 ADX71149
anxious
depression data which is expected in the first half of the year," said Tim
Dyer,
CEO of Addex. "We continue to explore strategic options to advance our
portfolio
of proprietary clinical and preclinical allosteric modulators, as well
as our
allosteric modulator discovery technology platform."

The new shares were placed at CHF2.75 per share, corresponding to a 5%
discount
to the volume weighted average price (VWAP) during the five preceding
trading
days prior to pricing. The 1,170,612 new issued registered shares will be
listed
on the SIX Swiss Exchange and their first day of trading will be the 9
August
2013. The new shares, with a par value of CHF 1 each, were issued
from the
Company's authorized share capital and represent 11.5% of the outstanding
share
capital after the transaction.

30 June 2013 Financial Update

Addex completed the half year ended 30 June 2013 with cash and cash
equivalents
of CHF4.5 million. The receipt of net proceeds from the private
placement
estimated at CHF3.1 million resulted in proforma adjusted cash and
cash
equivalents of CHF7.6 million.

About ADX71149

Addex' compound, ADX71149, an mGluR2 positive allosteric modulator (PAM)
jointly
developed in collaboration with Janssen Pharmaceuticals, Inc., is
currently in
Phase 2 clinical development for schizophrenia and anxious depression and
funded
entirely by Janssen Pharmaceutica NV. The schizophrenia and
anti-depressant markets represent worldwide sales of approximately $15
billion and $20 billion,
respectively. Under terms of the agreement with Janssen, Addex is
eligible to
receive EUR109 million in pre-launch milestones for these indications as
well as
low double-digit royalties on net sales of products arising from
the
partnership. Recently, Janssen presented data at the 2013 Annual Meeting
of the
American Psychiatric Association, on their Phase 2, first-in-patient,
trial
investigating ADX71149 as an adjunctive treatment in patients
with
schizophrenia. The data showed that ADX71149 met the primary
objectives of
safety and tolerability and that ADX71149 demonstrated an effect in
patients
with residual negative symptoms.

About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a development stage
company
focused on advancing innovative oral small molecules against rare
diseases
utilizing its pioneering allosteric modulation-based drug discovery
platform.
The Company's two lead products are being investigated in Phase 2
clinical
testing: dipraglurant (an mGlu5 negative allosteric modulator or NAM) is
being
developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia
(PD-LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive
allosteric
modulator or PAM) is being developed in collaboration with
Janssen
Pharmaceuticals, Inc., to treat both schizophrenia and anxiety as
seen in
patients suffering from major depressive disorder. Addex also has
several
preclinical programs including: GABA-BR positive allosteric modulator
(PAM) for
Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with
multiple
sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4
PAM for
MS, Parkinson's disease, anxiety and other diseases. Allosteric
modulators are
an emerging class of small molecule drugs which have the potential to be
more
specific and confer significant therapeutic advantages over
conventional
"orthosteric" small molecule or biological drugs. The Company uses
its
proprietary discovery platform to target receptors and other proteins
that are
recognized as essential for the therapeutic modulation of important
diseases
with unmet medical needs.

Disclaimer: The foregoing release may contain forward-looking statements
that
can be identified by terminology such as "seek", "not pursue", "not
approvable",
"continue", "believes", "believe", "will", "remained open to exploring",
"would", "could", or similar expressions, or by express or implied
discussions
regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its
business, the potential approval of its products by regulatory authorities,
or
regarding potential future revenues from such products. Such
forward-looking statements reflect the current views of Addex Therapeutics
regarding future
events, future economic performance or prospects, and, by their very
nature,
involve inherent risks and uncertainties, both general and specific,
whether
known or unknown, or any other factor that may materially differ from the
plans,
objectives, expectations, estimates and intentions expressed or implied in
such
forward-looking statements. Such factors may in particular cause actual
results
with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other
therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no
guarantee
that Addex Therapeutics will complete the restructuring and reduction of
its
liabilities or any financing nor that allosteric modulators of mGlu2,
mGlu4,
mGlu5, GABA-BR or other therapeutics targets will be approved for sale in
any
market or by any regulatory authority. Nor can there be any guarantee that
allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic
targets will achieve any particular levels of revenue (if any) in the
future. In
particular, management's expectations regarding allosteric modulators of
mGlu2,
mGlu4, mGlu5, GABA-BR or other therapeutic targets could be affected by,
among
other things, unexpected actions by our partners, unexpected regulatory
actions
or delays or government regulation generally; unexpected clinical trial
results,
including unexpected new clinical data and unexpected additional analysis
of
existing clinical data; competition in general; government, industry and
general
public pricing pressures; the company's ability to obtain or maintain
patent or
other proprietary intellectual property protection. Should one or more of
these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated,
believed,
estimated or expected. Addex Therapeutics is providing the information in
this
press release as of this date and does not undertake any obligation to
update
any forward-looking statements contained in this press release as a result
of
new information, future events or otherwise, except as may be required by
applicable laws.

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
other applicable laws; and

(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.